To expand its cellular imaging business, in July 2010 PerkinElmer Inc. acquired VisEn Medical Inc - a privately held in vivo molecular imaging technology company. Now fuctioing as a subsiduray of PerkinsElemer Health Sciences Inc, the smaller firm's core technology platforms were originally developed at the Massachusetts General Hospital and Harvard Medical School.enable revolutionary imaging of key disease states, activities and processes both in animals and humans. Supplemented by Patent acquired from Bayer, VisEn Medical, Inc.'s Fluorescence Molecular Tomographic (FMT) imaging systems and vivo imaging agents provide fluorescence molecular imaging performance in identifying, characterizing, and quantifying various ranges of disease biomarkers and therapeutic efficacy in vivo. The companys FMT systems and agents are used by research institutions and pharmaceutical companies in various applications, such as cancer research, inflammation, cardiovascular, skeletal, and pulmonary disease.
